HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- New treatments, new outcomes for refractory thyroid cancer
-
- Should lenvatinib be used as first-line therapy for slowly progressing radioiodine-refractory thyroid carcinoma?
- Potholes on the road to improved cancer outcomes John Sweetenham, MD, FRCP, FACP
- Integrating transition from pediatric- to adult-centered care: The APP’s role Susan M. Carson, MSN, RN, CPNP-PC; Trish Peterson, MSN, RN, CPNP-PC; Anne Nord, MSN, FNP-C; Deborah G. Harris, RN, MN, CPNP
- Mind the gap: Precision medicine shortcomings in NSCLC Howard (Jack) West, MD
- Enfortumab vedotin induces responses in advanced urothelial cancer
- Asparaginase discontinuation linked to inferior EFS in acute lymphoblastic leukemia
- Bispecific T-cell engager AMG 420 active, safe in heavily pretreated multiple myeloma
- Broader inclusion criteria could double the number of patients with lung cancer eligible for clinical trials
-
- Concurrent rituximab with cladribine enhances complete responses in untreated hairy cell leukemia
- CPX-351 regimen induces high response rates in pediatric relapsed acute myeloid leukemia
- Pembrolizumab for advanced hepatocellular carcinoma reduces mortality risk in 'technically ... negative study'
- Point-of-care bispecific targeting ‘offers new paradigm’ for CAR T-cell therapy
- SurVaxM vaccine appears ‘very promising’ for newly diagnosed glioblastoma
- Ribociclib plus endocrine therapy improves survival in advanced breast cancer subtype
- Rivaroxaban reduces VTE among ambulatory patients with pancreatic cancer
- Oropharynx cancer burden shifting to older individuals
-
- Strategies to identify sickle cell disease among refugees could reduce complications, costs
- Machine learning framework ‘much-needed advancement’ in prostate cancer risk assessment
- FDA approves Jakafi for acute graft-versus-host disease
- FDA approves Kanjinti, biosimilar to Herceptin
- FDA grants fast track, orphan drug designations to APR-246 for myelodysplastic syndrome
- Dana-Farber/Boston Children’s named nation’s best hospital for pediatric cancer